Biliary tract cancer.

Area of Science:

• Oncology
• Gastroenterology
• Molecular Biology

Background:

• Biliary tract cancers (BTCs), including cholangiocarcinoma and gallbladder cancer, are uncommon in high-income nations but pose significant health challenges in endemic regions.
• The incidence of intrahepatic cholangiocarcinoma is increasing worldwide, highlighting the need for updated understanding and management strategies.
• While surgery is curative, most patients present with advanced or metastatic disease, necessitating systemic treatment approaches.

Purpose of the Study:

• To provide a comprehensive update on the etiology, diagnosis, and treatment of biliary tract cancers.
• To discuss the evolving landscape of molecular classification and its impact on therapeutic strategies for BTC.
• To highlight the importance of multidisciplinary team management for optimal patient outcomes.

Main Methods:

• Review and synthesis of current literature on biliary tract cancer epidemiology, clinical presentation, and natural history.
• Analysis of advancements in diagnostic techniques and molecular subtyping of BTC.
• Evaluation of surgical approaches, systemic therapies, and emerging targeted treatments.

Main Results:

• Despite pooling data for research, distinct differences exist among BTC subtypes regarding their epidemiology, clinical behavior, and prognosis.
• Identification of specific molecular alterations (e.g., IDH1 mutations, FGFR2 fusions in intrahepatic cholangiocarcinoma) is paving the way for targeted therapies.
• Management by specialist multidisciplinary teams is crucial for optimizing surgical outcomes and overall patient care.

Conclusions:

• Biliary tract cancers require a nuanced approach, considering subtype-specific characteristics and molecular profiles.
• Targeted therapies based on molecular alterations represent a significant advancement in treating advanced BTC.
• Continued research and collaboration are essential to improve outcomes for patients with these challenging malignancies.